Bio-Techne Corporation

Equities

TECH

US09073M1045

Real-time Estimate Cboe BZX Other stock markets 13:08:00 2026-03-13 EDT			5-day change	1st Jan Change
50.78 ^USD	-1.34%		-5.52%	-13.42%

03-10	Bio-Techne Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 08:40 AM
03-03	Bio-Techne Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM

Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10

Published on 06/10/2025 at 12:05 pm EDT - Modified on 06/10/2025 at 08:05 pm EDT

S&P Capital IQ

Presenter Speech
Matthew Sykes (Analysts)

Good morning, everyone. My name is Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. And today, I have the pleasure of welcoming Jim

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bio-Techne Corporation

03-10	Bio-Techne Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 08:40 AM
03-03	Bio-Techne Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
02-17	Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%	MT
02-16	Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories	CI
02-16	Bio-Techne Corp's Ella platform receives CE-IVD marking, available for sale in EU	RE
02-11	Bio-Techne announces changes to its leadership team	RE
02-11	Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026	CI
02-05	UBS Adjusts Price Target on Bio-Techne to $79 From $70, Maintains Buy Rating	MT
02-05	TD Cowen Adjusts Price Target on Bio-Techne to $80 From $70, Maintains Buy Rating	MT
02-05	Stifel Nicolaus Adjusts Bio-Techne PT to $65 From $60, Maintains Hold Rating	MT
02-05	Baird Adjusts Price Target on Bio-Techne to $70 From $61, Maintains Neutral Rating	MT
02-05	Wells Fargo Adjusts Bio-Techne PT to $76 From $70, Maintains Overweight Rating	MT
02-05	Evercore ISI Adjusts Price Target on Bio-Techne to $68 From $62, Maintains In Line Rating	MT
02-05	Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $75, Maintains Outperform Rating	MT
02-04	Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on May 6, 2025.	CI